Table 2.
Presenting symptoms and treatment of management COVİD-19
| All (n: 64) | Cardiac involvement ( −) (n: 18) | Cardiac involvement ( +) (n: 46) |
p-value | |
|---|---|---|---|---|
| Presenting symptoms | ||||
| Chest pain, n (%) | 43 (67.1) | 14 (22.2) | 29 (37.0) | .259 |
| Shortness of breath/dyspnea, n (%) | 24 (37.5) | 6 (33.3) | 18 (39.1) | .667 |
| Management of COVİD-19 | ||||
| Favipiravir, n (%) | 51 (79.6) | 17 (94.4) | 34 (73.9) | .089 |
| Hydroxychloroquine, n (%) | 48 (75) | 15 (83.3) | 33 (71.7) | .336 |
| Glucocorticoids, n (%) | 2 (3.125) | 1 (5.6) | 1 (2.2) | .485 |
| Azithromycin, n (%) | 10 (15.6) | 2 (11.1) | 8 (17.4) | .534 |
COVID-19 coronavirus disease 2019